AGILE Trial: Frontline Axitinib Versus Sorafenib in mRCC

As part of their Peer Exchange Series, onclive.com presents a discussion of the AGILE Trial by one of the collaborators, Thomas Hutson, and moderated by Daniel J. George from the Duke Cancer Institute in the Clinical Developments in Renal Cell Carcinoma section.

Published online July 22, 2013.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s